Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
33 hedge funds and large institutions have $671K invested in Statera Biopharma, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
14% more funds holding
Funds holding: 29 → 33 (+4)
86% less capital invested
Capital invested by funds: $4.64M → $671K (-$3.97M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$356K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$141K |
| 3 |
VF
Virtu Financial
New York
|
+$135K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$127K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$88.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Potomac Capital Management
New York
|
-$878K |
| 2 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$354K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$337K |
| 4 |
Renaissance Technologies
New York
|
-$36.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$30.2K |
STAB Hedge Fund Activity: Q1 2022 in Review
33 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2022, worth a combined $671K — down 86% from $4.64M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new STAB positions and 7 closed out — a net gain of 5 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $356K. The largest seller was Potomac Capital Management, exiting entirely with an estimated $878K sold.
- 33 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2022, up from 29 in Q4 2021.
- Funds reported $671K of Statera Biopharma, Inc. Common Stock stock for Q1 2022, down 86% quarter-over-quarter.
- 12 funds opened new Statera Biopharma, Inc. Common Stock positions in Q1 2022 and 7 closed out, a net change of +5 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2022 was Empery Asset Management, an estimated $356K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q1 2022 was Potomac Capital Management, an estimated $878K sold.
Based on aggregated 13F filings for Q1 2022.